12.87
+0.03(+0.23%)
Currency In USD
| Previous Close | 12.84 |
| Open | 12.84 |
| Day High | 12.98 |
| Day Low | 12.76 |
| 52-Week High | 12.97 |
| 52-Week Low | 6.69 |
| Volume | 654,158 |
| Average Volume | 1.8M |
| Market Cap | 4.05B |
| PE | 1,287 |
| EPS | 0.01 |
| Moving Average 50 Days | 11.51 |
| Moving Average 200 Days | 9.2 |
| Change | 0.03 |
If you invested $1000 in Amneal Pharmaceuticals, Inc. (AMRX) since IPO date, it would be worth $857.43 as of December 24, 2025 at a share price of $12.87. Whereas If you bought $1000 worth of Amneal Pharmaceuticals, Inc. (AMRX) shares 5 years ago, it would be worth $2,905.19 as of December 24, 2025 at a share price of $12.87.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
GlobeNewswire Inc.
Dec 22, 2025 9:01 PM GMT
Approvals expand Amneal’s biosimilars portfolioCompany expects to commercialize six biosimilars across eight presentations by 2027 BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ
Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals
GlobeNewswire Inc.
Dec 09, 2025 9:01 PM GMT
Expands Amneal’s injectables portfolio with an essential medicine used in hospitals for emergency and perioperative care BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) to
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease
GlobeNewswire Inc.
Dec 05, 2025 1:00 PM GMT
Interim data show substantial improvements in “Good On” time compared to other oral CD/LD therapiesCREXONT delivered substantial “Off” time reductions, improved motor symptom control and provided a longer duration of benefit with each doseFindings hi